Back

Superluminal Medicines raises $60 million to advance obesity drug into Phase 1

Verifying
  • Superluminal Medicines closed a $60 million Series B financing led by BVF Partners, L.P.
  • $60 million will support a Phase 1 obesity trial expected by end-2026.
  • Superluminal continues collaborations, including an Eli Lilly and Company GPCR partnership.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.